Biotech News
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
<p>Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February.</p>
<ul style="list-style-type: disc;">
<li>
<strong>Guggenheim Securities SMID Cap Biotech Conference, New York, NY</strong>
<ul>
<li>Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m. EST</li>
<li>Webcast link: <a href="https://api.newsfilecorp.com/redirect/arZokHwG50">https://wsw.com/webcast/guggen2/adap/1969770</a>
</li>
</ul>
</li>
</ul>
<p>This event can also be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at <a href="https://api.newsfilecorp.com/redirect/2EVGMcQBYa">www.adaptimmune.com</a>. Following the event, a replay of the presentation will be made available.</p>
<p><strong>About Adaptimmune</strong><br>
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.</p>
<p><strong>Forward-Looking Statements</strong><br>
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</p>
<div id="contactInfo">
<p><strong>Adaptimmune Contact</strong><br>
<strong>Investor Relations</strong><br>
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations<br>
T : +1 215 825 9310<br>
M : +1 215 460 8920<br>
<a href="mailto:Juli.Miller@adaptimmune.com">Juli.Miller@adaptimmune.com</a></p>
<p><strong>Media Relations</strong><br>
Dana Lynch, Senior Director of Corporate Communications<br>
M: +1 267 990 1217<br>
<a href="mailto:Dana.Lynch@adaptimmune.com">Dana.Lynch@adaptimmune.com</a></p>
</div>
<p><img src="https://images.newsfilecorp.com/files/8845/239017_f0a5e67d747ccaa4_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo"></p>
<p>To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/MAxo0SGjLj">https://www.newsfilecorp.com/release/239017</a></p>
<p>SOURCE Adaptimmune Therapeutics PLC</p>
<p></p>